Evidence map›Paper›PMID 34019214›Full record

Trial reportInvestigational new drugs2021

Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study.

Daisuke Kotani, Takayuki Yoshino, Masahito Kotaka, Akihito Kawazoe, Toshiki Masuishi, Hiroya Taniguchi, Kentaro Yamazaki, Takeharu Yamanaka, Eiji Oki, Kei Muro and 5 more

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Investigational new drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04097444 (Quadruplet 1st Line Treatment of CAPOXIRI Plus Bevacizumab Versus FOLFOXIRI Plus Bevacizumab for mCRC, Multicenter Randomised Phase II Study), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04097444 phase2unknown statusnot on this map

Quadruplet 1st Line Treatment of CAPOXIRI Plus Bevacizumab Versus FOLFOXIRI Plus Bevacizumab for mCRC, Multicenter Randomised Phase II Study (QUATTRO-II)

TypeinterventionalSponsorChugai PharmaceuticalRan2019 to 2022Enrolled112ConditionsMetastatic Colorectal CancerArmsBevacizumab, 5-fluorouracil, Leucovorin calcium, Irinotecan hydrochloride, Oxaliplatin
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 1 country.

Daisuke KotaniDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa City, Chiba, 277-8577, Japan.
Takayuki YoshinoDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa City, Chiba, 277-8577, Japan.
Masahito KotakaGastrointestinal Cancer Center, Sano Hospital, Kobe, Japan.
Akihito KawazoeDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa City, Chiba, 277-8577, Japan.
Toshiki MasuishiDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Hiroya TaniguchiDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa City, Chiba, 277-8577, Japan.
Kentaro YamazakiDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Takeharu YamanakaDepartment of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan.
Eiji OkiDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kei MuroDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Yoshito KomatsuDepartment of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center, Sapporo, Japan.
Hideaki BandoDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Hironaga SatakeCancer Treatment Center, Kansai Medical University Hospital, Hirakata City, Japan.
Takeshi KatoDepartment of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan.
Akihito TsujiDepartment of Medical Oncology, Kagawa University Hospital, 1750-1 Ikenobe, Kita District, Miki, Kagawa, 761-0793, Japan. atsuji@med.kagawa-u.ac.jp.ORCID 0000-0003-4034-1945
National Cancer Center Hospital East · JPAichi Cancer Center · JPHokkaido University Hospital · JPKagawa University Hospital · JPKansai Medical University · JPKyushu University · JPOsaka National Hospital · JPShizuoka Cancer Center · JPYokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background FOLFOXIRI plus bevacizumab is the first-line treatment for metastatic colorectal cancer (mCRC) but demonstrates high neutropenia incidence among Asian patients. Hence, we conducted the randomized phase II QUATTRO-II study (ClinicalTrials.gov identifier: NCT04097444; Japan Registry of Clinical Trials identifier: jRTCs041190072) to evaluate the safety and efficacy of capecitabine, oxaliplatin, and irinotecan (CAPOXIRI) combination plus bevacizumab versus FOLFOXIRI plus bevacizumab, expecting a lower incidence of neutropenia without compromising the efficacy. Methods We investigated the recommended doses (RD) of oxaliplatin and irinotecan as a safety lead-in portion of Step 1 before initiating the randomized portion as Step 2. Four dose levels of CAPOXIRI (fixed dose of capecitabine, 1600 mg/m

Indexed as

AgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCamptothecinCapecitabineColorectal NeoplasmsDose-Response Relationship, DrugFemaleFluorouracilHumansIrinotecanLeucovorinMaleMaximum Tolerated DoseMiddle AgedAntineoplastic AgentsBevacizumabCamptothecinCapecitabineFluorouracilIrinotecanLeucovorinOrganoplatinum CompoundsOxaliplatinBevacizumabCAPOXIRIFOLFOXIRIMetastatic colorectal cancerTriplet

Identifiers

PMID34019214
PMCPMC8541955
OpenAlexW3161957147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.